Thermo Fisher Scientific has expanded its strategic partnership with Agios Pharmaceuticals to co-develop second companion diagnostic (CDx) for oncology.

As part of the agreement, the companies will jointly validate the biomarkers for a test that will use Thermo Fisher’s Oncomine Precision Assay, which runs on the new Ion Torrent Genexus System.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The test will be used globally to detect low-grade glioma (LGG) patients with isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) mutations who may be eligible for Agios’ investigational inhibitor vorasidenib (AG-881).

Vorasidenib is currently under evaluation in the Phase III INDIGO study.

Thermo Fisher Scientific clinical next-generation sequencing and oncology president Garret Hampton said: “The speed of the Genexus System in combination with the Oncomine Precision Assay has the potential to change the pace in which those diagnosed with LGG can be stratified and directed to a potentially more effective treatment in the future.

“We are committed to collaborating with leading pharmaceutical partners to make precision medicine accessible to more patients everywhere.”

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

According to the agreement, Thermo Fisher will maintain the rights to commercialise the new test globally and seek clearance from the regulatory agencies.

The companies initiated a partnership in 2017 to develop and commercialise a CDx to identify patients with IDH1 mutant cholangiocarcinoma who may be eligible for Agios’ TIBSOVO (ivosidenib or AG-120) as part of ClarIDHy Phase III clinical study.

In March, Thermo Fisher partnered with Janssen Biotech to develop a CDx to identify variant-positive patients for enrolment into clinical trials focused on non-small cell lung cancer (NSCLC).

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact